trending Market Intelligence /marketintelligence/en/news-insights/trending/iqcp4tdscyowrn0i2hnjqg2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Akari Therapeutics CEO steps down

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Akari Therapeutics CEO steps down

Akari Therapeutics PLC said CEO and director David Solomon resigned following an internal investigation that revealed he used the company's credit card for personal use.

Akari said it found Solomon violating the drugmaker's policies after incurring personal charges on the company's corporate credit cards.

Clive Richardson, Akari's COO, will head the company in the interim as it searches for a permanent CEO.

The news comes nearly a year after the drugmaker's previous CEO, Gur Roshwalb, resigned after having been found of violating a company policy.